MacroGenics, Inc. (MGNX) Posts 25% ORR in Phase 2 CCGC Interim Data
MacroGenics reported interim Phase 2 data for lorigerlimab, showing a 25% confirmed ORR in CCGC patients. The trial enrolled 16 patients, with 4 responding. Median PFS was 2.9 months, and the 6-month PFS rate was 33%. Enrollment of 20 more patients is ongoing. According to the company, the safety profile was manageable.
How this was made
The 30-second read
Why it matters
The interim 25% ORR could accelerate the timeline for a pivotal trial and attract partnership interest.
Market read
First disclosure of Phase 2 efficacy data; potential catalyst for stock movement.
What to watch
The trial is still early‑stage; durability and larger enrollment outcomes remain uncertain.
Background
MacroGenics (MGNX) is a clinical‑stage biotech developing antibody‑drug conjugates for cancer.
Ticker impact
MacroGenics reported interim Phase 2 data showing a 25% confirmed ORR in CCGC patients.
likely upside as market prices in the encouraging response rate.
Phase 2 data with a 25% ORR is materially better than typical early‑stage benchmarks, prompting buying interest.
Market effects
May boost sentiment for the broader oncology biotech sector.
Limited to U.S. biotech investors; no broader regional effect.
Modest global relevance, primarily affecting biotech-focused funds.
Counterpoint
Some investors may view the small patient cohort (4 responses) as insufficient for confidence.
Key entities
- companyMacroGenics, Inc.
Biotech firm reporting the trial data.